Pioneering ‘gene silencing drug’ for Alzheimer’s disease shows promise
June 15, 2023 | Histopathology
Over the duration of the study, the team examined two forms of tau protein. They discovered that those who received the highest dosage showed greater than 50% reduction in total tau and phosphor tau levels after 24 weeks.
Researchers have to perform trials on larger groups and a more diverse population of patients to confirm whether it leads to significant clinical benefits and to understand the extent to which the drug is able to slow the disease’s progression.